Evidence map›Paper›PMID 21613576›Full record

ReviewAmerican journal of physiology. Regulatory, integrative and comparative physiology2011

Maternal vasodilation in pregnancy: the emerging role of relaxin.

Kirk P Conrad

Open access · greenAbstract readReview
In one paragraph

Review in American journal of physiology. Regulatory, integrative and comparative physiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed
14.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 210 citations in OpenAlex.

  1. Trial
  2. Volenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Trial
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Managing Respiratory Failure in Late Pregnancy.Journal of clinical medicine · 2026
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Cardiovascular effects of relaxin-2: therapeutic potential and future perspectives.Clinical research in cardiology : official journal of the German Cardiac Society · 2024
    Review
  18. Article
  19. Review
  20. Placental and Renal Pathways Underlying Pre-Eclampsia.International journal of molecular sciences · 2024
    Review

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Kirk P ConradDepartment of Physiology and Functional Genomics, Department of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville, Florida 32610, USA. kpconrad@ufl.edu
Florida College · US

Funding

Relaxin: The 'Elusive'Vasodilator of PregnancyR01HL067937 · NHLBI · UNIVERSITY OF FLORIDA · PI CONRAD, KIRK P · 2001 to 2009
$2.2M
Mechanisms of Vasodilation in PregancyR01DK063321 · NIDDK · UNIVERSITY OF FLORIDA · PI CONRAD, KIRK P · 2002 to 2005
$1.1M
NITRIC OXIDE AND MATERNAL HEMODYNAMICS IN PREGNANCYR01HD030325 · NICHD · UNIVERSITY OF NEW MEXICO · PI CONRA, KIRK P · 1994 to 2001
$473k
GLOMERULAR FUNCTION/BLOOD PRESSURE--PREGNANCYK11HD000662 · NICHD · DARTMOUTH COLLEGE · PI CONRA, KIRK P · 1985 to 1989
–
NHLBI NIH HHS R01 HL067937NHLBI NIH HHS R01-HL-067937NHLBI NIH HHS R21-HL-093334NICHD NIH HHS K11-HD-00662NICHD NIH HHS R01-HD-030325NIDDK NIH HHS R01 DK063321NIDDK NIH HHS R01-DK-063321
6 · The paper itself

Abstract

Pregnancy is a unique physiological condition of profound maternal renal and systemic vasodilation. Our goal has been to unveil the reproductive hormones mediating this remarkable vasodilatory state and the underlying molecular mechanisms. In addition to advancing our knowledge of pregnancy physiology, reaching this goal may translate into therapeutics for pregnancy pathologies such as preeclampsia and for diseases associated with vasoconstriction and arterial stiffness in nonpregnant women and men. An emerging player is the 6 kDa corpus luteal hormone relaxin, which circulates during pregnancy. Relaxin administration to rats and humans induces systemic and renal vasodilation regardless of sex, thus mimicking the pregnant condition. Immunoneutralization or elimination of the source of circulating relaxin prevents renal and systemic vasodilation in midterm pregnant rats. Infertile women who become pregnant by donor eggs (IVF with embryo transfer) lack a corpus luteum and circulating relaxin, and they show a markedly subdued gestational increase in glomerular filtration rate. These data implicate relaxin as one of the vasodilatory reproductive hormones of pregnancy. There are different molecular mechanisms underlying the so-called rapid and sustained vasodilatory actions of relaxin. The former is mediated by Gα(i/o) protein coupling to phosphatidylinositol-3 kinase/Akt (protein kinase B)-dependent phosphorylation and activation of endothelial nitric oxide synthase, the latter by vascular endothelial and placental growth factors, and increases in arterial gelatinase(s) activity. The gelatinases, in turn, hydrolyze big endothelin (ET) at a gly-leu bond to form ET(1-32), which activates the endothelial ET(B) receptor/nitric oxide vasodilatory pathway.

Indexed as

AnimalsFemaleHumansMalePregnancyRelaxinVasodilationRelaxin

Identifiers

PMID21613576
PMCPMC3154715
OpenAlexW1974280379

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.